|
1
|
Lipworth L, Tarone RE and McLaughlin JK:
The epidemiology of renal cell carcinoma. J Urol. 176:2353–2358.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng B, Zhu H, Gu D, Pan X, Qian L, Xue
B, Yang D, Zhou J and Shan Y: MiRNA-30a-mediated autophagy
inhibition sensitizes renal cell carcinoma cells to sorafenib.
Biochem Biophys Res Commun. 459:234–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Breau RH and Blute ML: Surgery for renal
cell carcinoma metastases. Curr Opin Urol. 20:375–381. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bukowski RM: Systemic therapy for
metastatic renal cell carcinoma in treatment naive patients: A
risk-based approach. Expert Opin Pharmacother. 11:2351–2362. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ, Jonasch E, Agarwal N, Beard C,
Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh
IH, et al: Kidney cancer, version 3.2015. J Natl Compr Canc Netw.
13:151–159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Achermann C, Stenner F and Rothschild SI:
Treatment, outcome and prognostic factors in renal cell carcinoma-A
single center study (2000–2010). J Cancer. 7:921–927. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sonpavde G, Choueiri TK, Escudier B,
Ficarra V, Hutson TE, Mulders PF, Patard JJ, Rini BI, Staehler M,
Sternberg CN and Stief CG: Sequencing of agents for metastatic
renal cell carcinoma: Can we customize therapy? Eur Urol.
61:307–316. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
M Eel D: Utilization of sunitinib for
renal cell cancer: An egyptian university hospital experience.
Asian Pac J Cancer Prev. 17:3161–3166. 2016.PubMed/NCBI
|
|
10
|
Zheng WX, Yan F, Xue Q, Wu GJ, Qin WJ,
Wang FL, Qin J, Tian CJ and Yuan JL: Heme oxygenase-1 is a
predictive biomarker for therapeutic targeting of advanced clear
cell renal cell carcinoma treated with sorafenib or sunitinib. Onco
Targets Ther. 8:2081–2088. 2015.PubMed/NCBI
|
|
11
|
Rini BI and Atkins MB: Resistance to
targeted therapy in renal-cell carcinoma. Lancet Oncol.
10:992–1000. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Buczek M, Escudier B, Bartnik E, Szczylik
C and Czarnecka A: Resistance to tyrosine kinase inhibitors in
clear cell renal cell carcinoma: From the patient's bed to
molecular mechanisms. Biochim Biophys Acta. 1845:31–41.
2014.PubMed/NCBI
|
|
13
|
Jaramillo MC and Zhang DD: The emerging
role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev.
27:2179–2191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Magesh S, Chen Y and Hu L: Small molecule
modulators of Keap1-Nrf2-ARE pathway as potential preventive and
therapeutic agents. Med Res Rev. 32:687–726. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Calkins MJ, Johnson DA, Townsend JA,
Vargas MR, Dowell JA, Williamson TP, Kraft AD, Lee JM, Li J and
Johnson J: The Nrf2/ARE pathway as a potential therapeutic target
in neurodegenerative disease. Antioxid Redox Signal. 11:497–508.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ji L, Li H, Gao P, Shang G, Zhang DD,
Zhang N and Jiang T: Nrf2 pathway regulates
multidrug-resistance-associated protein 1 in small cell lung
cancer. PLoS One. 8:e634042013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D,
Lee YM, Ku SK, Jung Y and Kwak M: NRF2 blockade suppresses colon
tumor angiogenesis by inhibiting hypoxia-induced activation of
HIF-1α. Cancer Res. 71:2260–2275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Samatiwat P, Prawan A, Senggunprai L and
Kukongviriyapan V: Repression of Nrf2 enhances antitumor effect of
5-fluorouracil and gemcitabine on cholangiocarcinoma cells. Naunyn
Schmiedebergs Arch Pharmacol. 388:601–612. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Akhdar H, Loyer P, Rauch C, Corlu A,
Guillouzo A and Morel F: Involvement of Nrf2 activation in
resistance to 5-fluorouracil in human colon cancer HT-29 cells. Eur
J Cancer. 45:2219–2227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muglia VF and Prando A: Renal cell
carcinoma: Histological classification and correlation with imaging
findings. Radiol Bras. 48:166–174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moch H, Artibani W, Delahunt B, Ficarra V,
Knuechel R, Montorsi F, Patard JJ, Stief CG, Sulser T and Wild PJ:
Reassessing the current UICC/AJCC TNM staging for renal cell
carcinoma. Eur Urol. 56:636–643. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tan EY, Campo L, Han C, Turley H, Pezzella
F, Gatter KC, Harris AL and Fox SB: BNIP3 as a progression marker
in primary human breast cancer; opposing functions in in situ
versus invasive cancer. Clin Cancer Res. 13:467–474. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ooi A, Dykema K, Ansari A, Petillo D,
Snider J, Kahnoski R, Anema J, Craig D, Carpten J, Teh BT and Furge
KA: CUL3 and NRF2 mutations confer an NRF2 activation phenotype in
a sporadic form of papillary renal cell carcinoma. Cancer Res.
73:2044–2051. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gu S, Lai Y, Chen H, Liu Y and Zhang Z:
miR-155 mediates arsenic trioxide resistance by activating Nrf2 and
suppressing apoptosis in lung cancer cells. Sci Rep. 7:121552017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu MC, Ji JA, Jiang ZY and You QD: The
Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic
target: An update. Med Res Rev. 36:924–963. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu D, Duan X, Dong D, Bai C, Li X, Sun G
and Li B: Activation of the Nrf2 pathway by inorganic arsenic in
human hepatocytes and the role of transcriptional repressor Bach1.
Oxid Med Cell Longev. 2013:9845462013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deng C, Tao R, Yu SZ and Jin H: Inhibition
of 6-hydroxydopamine-induced endoplasmic reticulum stress by
sulforaphane through the activation of Nrf2 nuclear translocation.
Mol Med Rep. 6:215–219. 2012.PubMed/NCBI
|
|
29
|
Ildefonso CJ, Jaime H, Brown EE, Iwata RL,
Ahmed CM, Massengill MT, Biswal MR, Boye SE, Hauswirth WW, Ash JD,
et al: Targeting the Nrf2 signaling pathway in the retina with a
gene-delivered secretable and cell-penetrating peptide. Invest
Ophthalmol Vis Sci. 57:372–386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wan Hasan WN, Kwak MK, Makpol S, Wan Ngah
WZ and Mohd Yusof YA: Piper betle induces phase I & II genes
through Nrf2/ARE signaling pathway in mouse embryonic fibroblasts
derived from wild type and Nrf2 knockout cells. BMC Complement
Altern Med. 14:722014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hayes JD and McMahon M: NRF2 and KEAP1
mutations: Permanent activation of an adaptive response in cancer.
Trends Biochem Sci. 34:176–188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Geismann C, Arlt A, Sebens S and Schäfer
H: Cytoprotection ‘gone astray’: Nrf2 and its role in cancer. Onco
Targets Ther. 7:1497–1518. 2014.PubMed/NCBI
|
|
33
|
Yoo NJ, Kim YR and Lee SH: Expression of
NRF2, a cytoprotective protein, in gastric carcinomas. APMIS.
118:613–614. 2010.PubMed/NCBI
|
|
34
|
Ji L, Wei Y, Jiang T and Wang S:
Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer
and their relationships to clinicopathologic features and survival.
Int J Clin Exp Pathol. 7:1124–1131. 2014.PubMed/NCBI
|
|
35
|
Wang J, Zhang M, Zhang L, Cai H, Zhou S,
Zhang J and Wang Y: Correlation of Nrf2, HO-1, and MRP3 in
gallbladder cancer and their relationships to clinicopathologic
features and survival. J Surg Res. 164:e99–e105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Solis LM, Behrens C, Dong W, Suraokar M,
Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN,
et al: Nrf2 and Keap1 abnormalities in non-small cell lung
carcinoma and association with clinicopathologic features. Clin
Cancer Res. 16:3743–3753. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim WD, Kim YW, Cho IJ, Lee CH and Kim SG:
E-cadherin inhibits nuclear accumulation of Nrf2: Implications for
chemoresistance of cancer cells. J Cell Sci. 125:1284–1295. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Niture SK and Jaiswal AK: Nrf2 protein
up-regulates antiapoptotic protein Bcl-2 and prevents cellular
apoptosis. J Biol Chem. 287:9873–9886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rotblat B, Melino G and Knight RA: NRF2
and p53: Januses in cancer? Oncotarget. 3:1272–1283. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang M, An C, Gao Y, Leak RK, Chen J and
Zhang F: Emerging roles of Nrf2 and phase II antioxidant enzymes in
neuroprotection. Prog Neurobiol. 100:30–47. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Aborode FA, Raab A, Voigt M, Costa LM,
Krupp EM and Feldmann J: The importance of glutathione and
phytochelatins on the selenite and arsenate detoxification in
Arabidopsis thaliana. J Environ Sci (China). 49:150–161. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Niture SK, Kaspar JW, Shen J and Jaiswal
AK: Nrf2 signaling and cell survival. Toxicol Appl Pharmacol.
244:37–42. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
DeNicola GM, Karreth FA, Humpton TJ,
Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES,
et al: Oncogene-induced Nrf2 transcription promotes ROS
detoxification and tumorigenesis. Nature. 475:106–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mitsuishi Y, Taguchi K, Kawatani Y,
Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ and Calhoun
ES: Nrf2 redirects glucose and glutamine into anabolic pathways in
metabolic reprogramming. Cancer Cell. 22:66–79. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhong Y, Zhang F, Sun Z, Zhou W, Li ZY,
You QD, Guo QL and Hu R: Drug resistance associates with activation
of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by
down-regulating Nrf2-mediated cellular defense response. Mol
Carcinog. 52:824–834. 2013.PubMed/NCBI
|
|
46
|
Kim HR, Kim S, Kim EJ, Park JH, Yang SH,
Jeong ET, Park C, Youn MJ, So HS and Park R: Suppression of
Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung
cancer A549 cells toward cisplatin. Lung Cancer. 60:47–56. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Arlt A, Sebens S, Krebs S, Geismann C,
Grossmann M, Kruse ML, Schreiber S and Schäfer H: Inhibition of the
Nrf2 transcription factor by the alkaloid trigonelline renders
pancreatic cancer cells more susceptible to apoptosis through
decreased proteasomal gene expression and proteasome activity.
Oncogene. 32:4825–4835. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li QK, Singh A, Biswal S, Askin F and
Gabrielson E: KEAP1 gene mutations and NRF2 activation are common
in pulmonary papillary adenocarcinoma. J Hum Genet. 56:230–234.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lim JH, Kim KM, Kim SW, Hwang O and Choi
HJ: Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: Novel
cytoprotective mechanism against oxidative damage. Pharmacol Res.
57:325–331. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang Y, Guan L, Wang X, Wen T, Xing J and
Zhao J: Protection of chlorophyllin against oxidative damage by
inducing HO-1 and NQO1 expression mediated by PI3K/Akt and Nrf2.
Free Radic Res. 42:362–371. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mayer IA and Arteaga CL: The PI3K/AKT
pathway as a target for cancer treatment. Annu Rev Med. 67:11–28.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
West KA, Castillo SS and Dennis PA:
Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Makhov PB, Golovine K, Kutikov A, Teper E,
Canter DJ, Simhan J, Uzzo RG and Kolenko VM: Modulation of Akt/mTOR
signaling overcomes sunitinib resistance in renal and prostate
cancer cells. Mol Cancer Ther. 11:1510–1517. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen YL, Ge GJ, Qi C, Wang H, Wang HL, Li
LY, Li GH and Xia LQ: A five-gene signature may predict sunitinib
sensitivity and serve as prognostic biomarkers for renal cell
carcinoma. J Cell Physiol. 233:6649–6660. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Imbulgoda A, Heng DY and Kollmannsberger
C: Sunitinib in the treatment of advanced solid tumors. Recent
Results Cancer Res. 201:165–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Grassi P, Verzoni E, Porcu L, Iacovelli R,
de Braud F and Procopio G: Sites of disease as predictors of
outcome in metastatic renal cell carcinoma patients treated with
first-line sunitinib or sorafenib. Ther Adv Urol. 7:59–68. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yang F, Jove V, Xin H, Hedvat M, Van Meter
TE and Yu H: Sunitinib induces apoptosis and growth arrest of
medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling
pathways. Mol Cancer Res. 8:35–45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Deng X, Rui W, Zhang F and Ding W: PM2.5
induces Nrf2-mediated defense mechanisms against oxidative stress
by activating PIK3/AKT signaling pathway in human lung alveolar
epithelial A549 cells. Cell Biol Toxicol. 29:143–157. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Singh A, Boldin-Adamsky S, Thimmulappa RK,
Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F,
Watson WH, et al: RNAi-mediated silencing of nuclear factor
erythroid-2-related factor 2 gene expression in non-small cell lung
cancer inhibits tumor growth and increases efficacy of
chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
|
